

## TABLE OF CONTENTS

<b>COVER PAGE .....</b>	<b>i</b>
<b>APPROVAL PAGE .....</b>	<b>ii</b>
<b>REVISION FREE LETTER OF STATEMENT .....</b>	<b>iii</b>
<b>PLAGIARISM FREE STATEMENT .....</b>	<b>iv</b>
<b>ACKNOWLEDGEMENTS.....</b>	<b>v</b>
<b>PREFACE.....</b>	<b>vi</b>
<b>TABLE OF CONTENTS.....</b>	<b>viii</b>
<b>LIST OF FIGURES .....</b>	<b>xii</b>
<b>LIST OF TABLES .....</b>	<b>xiv</b>
<b>LIST OF ABBREVIATIONS .....</b>	<b>xv</b>
<b>LIST OF APPENDICES .....</b>	<b>xviii</b>
<b>ABSTRACT .....</b>	<b>ii</b>
<b>CHAPTER 1 .....</b>	<b>1</b>
A. Background .....	1
B. Problem Statements .....	4
C. Research Objectives .....	4
D. Research Benefits .....	5
E. Literature Review .....	6
1. SARS-CoV 2 .....	6
2. COVID-19: Epidemiology, Clinical Manifestation, Pathology, and Treatment .....	8
3. SARS CoV-2 RP1a as a Target Therapy .....	12
4. Drug Repurposing .....	14
5. Cheminformatics Analysis for Drug Repurposing.....	17
a. Definition, Comparison between Bioinformatics and Their Parts.....	17
1).Cheminformatic database .....	18

2). Databases Searching Tools .....	19
3). Property Prediction Tools .....	20
b. Ligand-Based Virtual Screening (LBVS) .....	20
1). Definition, List of LBVS Methods .....	20
2). Descriptor-Based Virtual Screening .....	21
a). Substructure Keys-based Fingerprints .....	23
b). Topological Keys-based Fingerprints .....	24
c). Circular Fingerprints .....	25
3). Scaffold Mining & Clustering Method .....	26
4). Maximum Common Substructure (MCS) Aligmnet and SMiles ARbitrary Target Specification (SMARTS) .....	31
c. Machine Learning for Ligand-based Virtual Screening .....	33
1). Definition, Purpose, Evaluation of Machine Learning .....	33
a). Confusion Matrix .....	36
b). Cohen's Kappa .....	37
2). List of Most Common Supervised Classification ML .....	38
a). Random Forest Classifier .....	38
b). Artificial Neural Network .....	40
c). Support Vector Machine .....	41
6. Protein-Protein Interaction (PPI) Analysis .....	44
7. Programmatic Data Access with Open-Source Facilities .....	45
8. Theoretical Basics .....	46
9. Empirical Statement .....	49
<b>CHAPTER II .....</b>	<b>50</b>
A. Research Plan .....	50

B. Research Variables Operational Definition.....	51
C. Research Materials .....	52
D. Research Tools .....	53
1. Computer Specification.....	53
2. Software .....	53
a. Konstanz Information Miner (KNIME).....	53
b. Cytoscape.....	54
E. Research Location .....	54
F. Research Steps.....	55
1. Preparation of RPl <sub>a</sub> Protein.....	56
2. Programmatic Data Access: Retrieval of Protein-ligand structure from Protein Data Bank .....	56
3. Programmatic Data Access: Bioactivity Research of Potential Ligands from ChEMBL and PubChem.....	57
4. Gadaleta Standardization.....	59
5. Fetch substructure using Bemis-Murcko Scaffolds & Hierarchical Clustering .....	60
6. Generate and Calculate Maximum Common Substructure (MCS).....	60
7. Preparation of Potential Compounds Database and Virtual Screening: Substructure Search.....	61
8. Ligand-based Machine Learning Model Preparation.....	61
9. Model Usage to Predict Activity Score.....	62
10. Protein-protein Interaction Network Generation and Literature Analysis	62
<b>CHAPTER III .....</b>	<b>64</b>
A. Research Concept.....	64
B. Retrieval & Analysis of Protein & Ligand Target Data.....	66
C. Scaffold Mining, Hierarchical Clustering, and MCS Alignment.....	70
D. Candidate Compound Screening with Created MCS .....	77
E. Ligand-based Machine Learning Model Analysis .....	80

1. Random Forest .....	83
2. Artificial Neural Network .....	84
3. Support Vector Machine .....	84
F. Machine Learning Model Testing .....	85
G. Protein-Protein Interaction Analysis of Target Protein .....	87
H. Literature Analysis of Screened Drug Results .....	93
I. Molecular Mechanism of Screened Drug in RP1a Inhibition .....	101
J. Study Limitations .....	104
<b>CHAPTER IV.....</b>	<b>106</b>
A. Conclusions .....	106
B. Recommendations .....	107
<b>REFERENCES.....</b>	<b>109</b>
<b>APPENDICES .....</b>	<b>126</b>

## LIST OF FIGURES

<b>Figure 1.</b> Classification of SARS-CoV-2 Virus .....	7
<b>Figure 2.</b> Pathophysiology of SARS-CoV-2 Leads to RAAS Disturbance and Inflammation .....	11
<b>Figure 3.</b> Genetic Material (RNA) of SARS-CoV-2 Enters the Host Cell and Borrows Ribosomes to Translate Into 16 Non-Structural Proteins (NSPs) .....	13
<b>Figure 4.</b> Traditional Drug Discovery vs. Drug Repurposing Method .....	16
<b>Figure 5.</b> List of Virtual Screening Approach.....	21
<b>Figure 6.</b> Example of Substructure-based Fingerprint Similarity .....	24
<b>Figure 7.</b> Example of Hashed Fingerprint Similarity Approach .....	25
<b>Figure 8.</b> Definitions of Different Types of Fragments in a Molecule .....	28
<b>Figure 9.</b> All Types of Linkage Method of Hierarchical Clustering .....	30
<b>Figure10.</b> Illustration of Bemis-Murcko Fragmentation Algorithm with Hierarchical Clustering .....	31
<b>Figure 11.</b> Illustration of implementation of MCS.....	33
<b>Figure 12.</b> Illustration of Confusion Matrix .....	36
<b>Figure 13.</b> Illustration of Random Forest Classifier.....	39
<b>Figure 14.</b> Illustration of Artificial Neural Network .....	41
<b>Figure 15.</b> Illustration of Support Vector Machine .....	42
<b>Figure 16.</b> KNIME Drug Repurposing Workflow .....	65
<b>Figure 17.</b> KNIME Workflow of PDB Protein-ligand Retrieval .....	66
<b>Figure 18.</b> KNIME Workflow of ChEMBL Bioactivities Retrieval .....	67
<b>Figure 19.</b> KNIME Workflow of PubChem Bioactivities Retrieval .....	68
<b>Figure 20.</b> KNIME Workflow of Creating Murcko Scaffold.....	71
<b>Figure 21.</b> KNIME Workflow of Hierarchical Clustering .....	72
<b>Figure 22.</b> KNIME Workflow of MCS Calculation.....	73
<b>Figure 23.</b> KNIME Substructure Screening Workflow.....	78

<b>Figure 24.</b> Chart Visualization of Screened Drug List from DrugBank for Each Target .....	79
<b>Figure 25.</b> KNIME Workflow of Fingerprint Similarity using MACCS and ECFP4 (Morgan) and Machine Learning Model Creation with 10-fold k-Cross-validation.....	82
<b>Figure 26.</b> ROC Curve of Each ML Algorithm with MACCS Fingerprint Method: (a) Random Forest, (b) Artificial Neural Network, and (c) Support Vector Machine .....	83
<b>Figure 27.</b> KNIME Workflow of Model Usage for Compounds Prediction.....	86
<b>Figure 28.</b> List of Screened Candidate Compounds with >90% Confidence .....	87
<b>Figure 29.</b> Protein-protein Interaction Network of NSP5 or 3CLpro .....	90
<b>Figure 30.</b> Top 10 Proteins that Interact with NSP5 after analyzed by 'Degree' Hubba Node Parameter in Cytoscape.....	90
<b>Figure 31.</b> Suggested Molecular Mechanism of RP1a with Other Proteins.....	103

## LIST OF TABLES

<b>Table I.</b> Comparisons Between Databases, Data Formats, Prediction Methods, Visualization Software and Manipulation Tools Used in Bioinformatics and Cheminformatics.....	17
<b>Table II.</b> Research Variables .....	51
<b>Table III.</b> Number of Compounds Available from Different Databases .....	69
<b>Table IV.</b> Top 15 list of Clusters of Enriched Maximum Common Substructures from Murcko Framework with Its Number of Successfully Screened Candidate compounds.....	74
<b>Table V.</b> Summary of Machine Learning Parameter with Consideration to Use the Model for Prediction for 3CLpro Targeted Therapy .....	81
<b>Table VI.</b> Top 10 Protein Interaction of 3CLpro by 'Degree' Hubba Node with Their Physiological Roles .....	90
<b>Table VII.</b> Literature Analysis of Top 5 Compounds from Top 5 Scaffolds from RF MACCS Model Predictor .....	95

## LIST OF ABBREVIATIONS

3CLpro	3-Like-Chymotrypsin Protease
AAK1	Adaptor-associated Protein Kinase 1
AID	PubChem Assay ID
ANN	Artificial Neural Network
API	Application Programming Interface
ACE2	Angiotensin-Converting Enzyme II
ATP	Adenosine Tri Phosphate
AUC	Area Under Curve
CatB/L	Cysteine Protease Cathepsin B & L
CART	Classification and Regression Tree
CCR5	C-C Chemokine Receptor Type 5
CDER	Centre of Drug Evaluation and Research
ChEMBL	Chemical European Molecular Biology Laboratory
CID	PubChem Compound ID
COVID-19	Coronavirus Disease 2019
DDX39B	DEAD-box helicase 39B
DNA	Deoxy Ribonucleic Acid
ECFP	Extended-Connectivity Fingerprints
EIF2S1	Eukaryotic Translation Initiation Factor 2 subunit 1
EIF4A1	Eukaryotic Translation Initiation Factor 4A1
FACT	Facilitates Chromatin Transcription
FDA	Food and Drug Administration
HCoV	Human Coronavirus
HE-protein	Membrane Glycoprotein
InChI	IUPAC-international Chemical Identifier
IND	Investigational New Drug



IFN	Interferon
ISG15	Interferon-Stimulated Gene 15
IUPAC	International Union of Pure and Applied Chemistry
JKN	Jaminan Kesehatan Nasional
JSON	JavaScript Object Notation
KEGG	Kyoto Encyclopedia of Genes and Genomes
KNIME	Konstanz Information Miner
LBVS	Ligand-based Virtual Screening
LBML	Ligand-based Machine Learning
LRPPRC	Leucine-Rich Pentatricopeptide Repeat Containing
MACCS	Molecular Access System
MAPK	Mitogen-activated Protein Kinase
MAVS	Mitochondrial Antiviral-Signaling Protein
MCS	Maximum Common Substructure
MYO1B	Myosin IB
N-protein	Nucleocapsid Protein
NDA	New Drug Application
NEMO	NF $\kappa$ B Essential Modulator
NSAID	Non-Steroidal Anti-Inflammatory Drug
NSP	Non-Structural Protein
ORF	Open Reading Frame
PDB	Protein Data Bank
PharmGKB	Pharmacogenomic Knowledge Base
PLpro	Papain Like Protease
PSMB9	Proteasome 20S Subunit Beta 9
RAAS	Renin Angiotensin Aldosterone System
RDKit	Rational Discovery Kit
RF	Random Forest
RIG-I	Retinoic acid-inducible gene I

RNA	Ribonucleic Acid
ROC	Receiver Operating Characteristic
S-protein	Spike Protein
SAR	Structure-Activity Relationship
SARS-CoV	Severe Acute Respiratory Syndrome Coronavirus
SDF	Structured Data Format
SDHA	Succinate Dehydrogenase complex flavoprotein subunit A
SM-protein	Small Membrane Protein
SMARTS	SMILES Arbitrary Target Specification
SMILES	Simplified Molecular-Input Line-Entry System
SMOTE	Synthetic Minority Over-sampling Technique
SPTBN2	Spectrin Beta, Non-Erythrocytic 2
SVM	Support Vector Machine
TFAM	Mitochondrial transcription factor A
TMRPSS2	Transmembrane Protease Serine 2
TNF- $\alpha$	Tumor Necrosis Factor-alpha
tRNA	Transcriptional RNA
UniProt	Universal Protein Resources
VOC	Variant of Concern
Xpath	XML Path Language
WHO	World Health Organization
RP1a	Replicase Polyprotein 1a

## LIST OF APPENDICES

<b>Appendix 1.</b> QR Code (Github) to Access the Thesis Files.....	126
<b>Appendix 2.</b> Detailed Version of Parameter Set in Controlled Variable in KNIME Application.....	126
<b>Appendix 3.</b> Confusion Matrix of RF Classifier for 3CLpro.....	130
<b>Appendix 4.</b> Confusion Matrix of ANN Classifier for 3CLpro .....	130
<b>Appendix 5.</b> Confusion Matrix of SVM Classifier for 3CLpro .....	130
<b>Appendix 6.</b> Binary Labelling KNIME Workflow .....	131
<b>Appendix 7.</b> KNIME Workflow of Gadaleta Standardization.....	132
<b>Appendix 8.</b> Step 1 of Ligand Pre-processing from PDB .....	133
<b>Appendix 9.</b> PDB Property Downloader and Extractor .....	134
<b>Appendix 10.</b> Step 3 PDB Retrieval .....	135
<b>Appendix 11.</b> ChEMBL Step 2 to Find Bioactivity Data .....	136
<b>Appendix 12.</b> ChEMBL Step to Request the PubMed ID and Download the ChEMBL Document to Enhance the Evidence .....	137
<b>Appendix 13.</b> ChEMBL and PubChem Workflow to Extract Canonical SMILES .....	138
<b>Appendix 14.</b> PubChem Step to Request Compound Name .....	139
<b>Appendix 15.</b> Ligand Retrieval Post-Processing Workflow .....	140
<b>Appendix 16.</b> ML Model Evaluation .....	141
<b>Appendix 17.</b> Complete List of Screened Drug Compounds by RF MACCS model with Prediction Confidence Score >90% .....	141